Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world.
read more
Levi Garraway M.D., Ph.D. ā Senior Vice President of Global Development & Medical Affairs - Oncology Business at Eli Lilly and Company
Executive Bio
Dr. Levi Garraway, M.D., Ph.D., has been Senior Vice President of Global Development & Medical Affairs - Oncology Business at Eli Lilly and Company since January 1, 2017. Dr. Garraway serves as a Founding Advisor at Foundation Medicine, Inc. Dr. Garraway serves as an Assistant Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School. He is also a faculty member of Dana-Farber's Center for Cancer Genome Discovery and an Associate Member of the Broad Institute, where he leads several large cancer genome analyses and functional genomics efforts in the Broad Cancer Program. Dr. Garraway leads a 16-member investigative team in cancer genomics at Dana-Farber and the Broad Institute. His research has informed several gene targets and 'druggable' pathways relevant to the genesis and therapeutic vulnerabilities of melanoma and other malignancies. Dr. Garraway's group developed OncoMap, a platform for systematic cancer mutation profiling that has inspired multiple personalized cancer medicine efforts across the U.S. and beyond. Dr. Garraway is director of the Joint Center for Cancer Precision Medicine, which spans Harvard teaching hospitals: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital and the Broad Institute of MIT and Harvard. He is also co-leader of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center. In addition to his work at Harvard, Dr. Garraway is on the boards of major cancer centers, including Sloan Kettering, MD Anderson and Ohio State and he is chairman of several major National Institutes of Health (NIH) committees. He received awards including Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from AACR, the New Innovator Award from the NIH and an Outstanding Investigator Award from the National Cancer Institute. Dr. Garraway has been the recipient of several awards and honors, including the Minority Scholar Award from the American Association of Cancer Research, the Partners in Excellence Award from the Massachusetts General Hospital and the Career Award in the Biomedical Sciences from the Burroughs-Wellcome Fund. In the fall of 2007, Dr. Garraway was awarded one of the first prestigious New Innovator Awards from the National Institutes of Health, worth $1.5 million over five years. In 2009, Dr. Garraway was president of the American Society for Clinical Investigation. He is graduate at Harvard Medical School.
Executive Team Culture Ratings from Eli Lilly and Company Employees
TOP
15%
Eli Lilly and Company's Executive Team scores in the Top 15%
of similar sized companies on Comparably
of similar sized companies on Comparably
Eli Lilly and Company's Executive Team at a Glance
Based on 142 ratings, Eli Lilly and Company's employees are very satisfied with their Executive Team and give them an āA-ā or 76/100. On average, Men provided higher ratings for their Executive Team compared to Women. Also, the Operations department thinks more highly of the Executive Team relative to the Product department.
Eli Lilly and Company's Executive Team ranks in the Top 20% of other companies in Indianapolis, IN and Top 15% of other companies on Comparably that also have 10,000+ Employees.
×